Archimed, KKR and Novo target medical genetics; untapped women’s health investments could generate $14bn in returns

Private equity bets on the pharma and life sciences sector.

Morning Hubsters,

Happy Fri-yay! John R. Fischer here with the US Wire from the New York newsroom.

We’re starting off with a listicle of mine on a pharma and life sciences sector in the realm of personalized healthcare that has attracted the likes of ArchimedKKR and Novo Holdings.

Share this